Publications by authors named "V Simeon"
Article Synopsis
- Previous models for predicting weight gain haven't been very effective, leading researchers to explore both traditional environmental factors and genetic markers to enhance accuracy.* -
- A study involving nearly 246,000 participants found that environmental factors provided good predictive ability for weight gain, while genetic models performed poorly, especially at mid-late adulthood.* -
- The research suggests that environmental factors should be incorporated into prevention strategies, and that genetic factors may be more relevant in predicting weight gain earlier in life.*
Article Synopsis
- In ovarian cancer, a comprehensive study examined various metabolism-related markers to understand their prognostic value, but results showed mixed outcomes in large patient groups.
- The study used advanced techniques on tissue samples from over 300 patients to analyze markers tied to glycolysis, glutamine metabolism, and hypoxia, but found that only one marker (GLS) hinted at a connection to patient survival, which was not statistically significant after adjustments.
- Ultimately, the research highlights the diversity of metabolism markers in ovarian cancer and suggests their expression patterns may still be relevant for future drug development, even if they don't currently correlate with treatment outcomes.
Article Synopsis
- There are currently no specific biomarkers to identify patients with advanced ovarian carcinoma who are responsive to bevacizumab (BEV), a key treatment option.
- A study analyzed TP53 mutations and p53 expression in advanced ovarian cancer patients undergoing BEV treatment, finding that unclassified missense TP53 mutations significantly improved overall survival.
- The results suggest that unclassified TP53 mutations could serve as a favorable prognostic indicator in these patients, indicating the need for further research to explore their potential role in predicting treatment outcomes.
Alcohol withdrawal syndrome (AWS) is defined as the cessation or reduction in heavy and prolonged alcohol use within several hours to a few days of cessation. The recommended first-line therapy for AWS ranging from mild to severe or complicated remains benzodiazepines; in cases where benzodiazepines are not adequate in controlling persistent autonomic hyperactivity or anxiety, dexmedetomidine could be utilized. The possible advantage of dexmedetomidine compared to benzodiazepines is that it does not cause respiratory depression, thus reducing the risk of intubation and hospitalization in the ICUs, with the potential reduction in healthcare costs.
View Article and Find Full Text PDFA "spontaneous" correction of the Class II malocclusion has been described after maxillary expansion (ME) treatment. The aim of the present review was to systematically summarize changes in the sagittal dentoskeletal parameters of growing Class II patients after ME. The study protocol was developed according to the PRISMA statement and registered in PROSPERO before literature search, data extraction and analysis.
View Article and Find Full Text PDF